N/A N=29 Electric Blower Based Ventilator Used During Procedural Sedation
Apnea During Procedural Sedation
Primary: Percentage of Time the Patient Will Experience Apnea — 11 % time in apnea of total study duration
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=53 Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma
Sarcoma, Alveolar Soft Part
Primary: Minimal Response Rate in Pediatric Participants With Alveolar Soft Part Sarcoma (ASPS) — 0 Participants
N/A N=176 Post-release Retention in HIV Care for Ex-inmates in South Africa
Hiv · Adherence, Patient
Primary: Number of Participants in Care at Six Months — 67; 19 Participants
Phase 2 N=24 Study to Evaluate Effects of Emixustat Hydrochloride in Subjects With Proliferative Diabetic Retinopathy
Proliferative Diabetic Retinopathy
Primary: Change in Aqueous Humor Concentration of the Following Biomarkers:IL-6, IL-8, IP-10, PDGF-AA, TGFβ-1, MCP-1, IL-1β, and VEGF, to be Reported in pg/mL Values — 45.6; 4.9…
N/A N=33 Feasibility of Laryngeal Mask Airway Gastro on Patients Undergoing Endoscopic Retrograde Cholangiopancreatography for Pancreas and Bile Duct Disorders
Bile Duct Disorder · Endocrine Pancreas Disorder
Primary: The Number of Participants With Overall Success of ERCP With LMA Gastro — 28 Participants
Phase 1 N=48 Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects
Type 2 Diabetes Mellitus
Primary: Cmax (Maximum Observed Plasma Concentration) — 161.675; 193.366; 97.811; 117.001 ng/mL
Phase 3 N=471 Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine in Older Adults Who Received a Primary Vaccination (3 or More Years Earlier) in Study MET49
Meningococcal Infection (Healthy Volunteers)
Primary: Stage I: Percentage of Participants With Seroresponse for Meningococcal Serogroups A, C, W & Y Measured by Serum Bactericidal Assay Using Human Complement (hSBA) After…
Phase 3 N=17 Study to Assess the Efficacy and Safety of Ryanodex as Adjuvant Treatment in Subjects With EHS
Exertional Heat Stroke
Primary: Cumulative Incidence of Recovery of Level of Consciousness Defined as a Glasgow Coma Scale (GCS) GCS ≥ 13 [Time Frame: 90 Minutes Post-randomization] — 4; 2 Participants
Early Phase 1 N=24 Augmenting Growth Hormone to Ameliorate Nonalcoholic Fatty Liver Disease in Adolescents
NAFLD
Primary: Change in Hepatic Fat Fraction — -3.0; 0.3 Percent (Hepatic fat fraction, percent)
Phase 2 N=64 High Dose Intravenous Thiamine for the Prevention of Delirium in Allogeneic Hematopoietic Stem Cell Transplantation
Hematopoietic Stem Cell Transplantation · Delirium · Thiamine Deficiency
Primary: Percentage of Participants With Delirium — 25; 21 percentage of participants
N/A N=1,633 Silicone Adhesive Multilayer Foam Dressings to Prevent Pressure Ulcer
Pressure Ulcer
Primary: Number of Participants Who Developed a New Pressure Ulcer Category 2 or Worse on Sacrum, Heels or Greater Trochanter — 43; 34 Participants — p=0.04
N/A N=23 eCoin for OAB Feasibility Follow-on Study
Overactive Bladder · Urge Incontinence · Incontinence, Urinary
Primary: Change From Baseline in Urgency Urinary Incontinence Episodes as Measured by a 3-day Voiding Diary. — -2.2 episodes/day
N/A N=30 Clinical Outcomes After Treatment With RestrataTM Wound Matrix in Diabetic Foot Ulcers (DFU)
Diabetic Foot Ulcer
Primary: Percentage of Participants With Wound Closed — 75 percentage of participants
Phase 3 N=217 Evaluation of TRC101 in Subjects With Metabolic Acidosis Associated With Chronic Kidney Disease
Metabolic Acidosis
Primary: Subjects With Change From Baseline in Serum Bicarbonate of ≥ 4 mEq/L or Serum Bicarbonate Within the Normal Range — 59.2; 22.5; 55.8; 21.3 percentage of participants…
Phase 1 N=82 MEK and MET Inhibition in Colorectal Cancer
Solid Tumor · Colorectal Cancer
Primary: Maximal Tolerated Dose (MTD) of PD-0325901 and PF-02341066 /PF-02341066 or Binimetinib With PF-02341066 — 0; 0; 0; 1 Dose Limiting Toxicities (DLTs)